Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Silence Therapeutics plc (SLN) is the issuer named in an amended ownership report in which Tetragon Financial Group Limited, its investment manager Tetragon Financial Management L.P., and the manager’s principals Patrick G. G. Dear and Reade E. Griffith each report the same shared beneficial ownership of 9,878,565 ordinary shares, or 5.3% of the class. The position is represented by 3,292,855 American Depositary Shares (ADSs) and includes 1,500,000 shares issuable upon exercise of call options, underlying 500,000 ADSs. Each ADS represents three ordinary shares. The 5.3% calculation uses 186,461,401 ordinary shares outstanding, as reported after completion of the offering and full exercise of the underwriters’ over-allotment option.
Key Figures
Shared beneficial ownership:9,878,565 ordinary sharesPercent of class:5.3%American Depositary Shares:3,292,855 ADSs+3 more
6 metrics
Shared beneficial ownership9,878,565 ordinary sharesSame reported amount for each reporting person
Percent of class5.3%Beneficial ownership percentage
American Depositary Shares3,292,855 ADSsRepresentation of the reported ordinary-share position
Shares issuable upon call-option exercise1,500,000 ordinary sharesUnderlying 500,000 ADSs
ADSs underlying call options500,000 ADSsADSs issuable upon call-option exercise
Ordinary shares outstanding186,461,401 ordinary sharesBasis for the reported ownership percentage
Key Terms
beneficial ownership, shared voting power, shared dispositive power, American Depositary Shares, +1 more
5 terms
beneficial ownershipfinancial
"Amount beneficially owned"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
shared voting powerfinancial
"Shared Voting Power 9,878,565.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive powerfinancial
"Shared Dispositive Power 9,878,565.00"
American Depositary Sharesfinancial
"Each ADS represents three Shares"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
call optionsfinancial
"issuable upon exercise of call options"
A call option is a contract that gives its buyer the right, but not the obligation, to buy a specific number of shares at a predetermined price within a set time. Think of it like a refundable reservation to purchase a stock later at today’s agreed price: investors use calls to profit from expected price rises with smaller upfront cost than buying the stock outright, or to hedge and manage exposure, while the most they can lose is the amount paid for the contract.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many SLN shares do the Tetragon reporting persons beneficially own?
The reporting persons each report shared beneficial ownership of 9,878,565 ordinary shares, or 5.3% of the class. The same reported position is represented by 3,292,855 ADSs.
How many SLN shares in the reported position are issuable upon call-option exercise?
The reported position includes 1,500,000 ordinary shares issuable upon exercise of call options, underlying 500,000 ADSs. Each ADS represents three ordinary shares.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
Silence Therapeutics plc
(Name of Issuer)
Ordinary Shares, nominal value 0.05 GBP per share
(Title of Class of Securities)
G8128Y157
(CUSIP Number)
10/05/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
G8128Y157
1
Names of Reporting Persons
Tetragon Financial Group Limited
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
GUERNSEY
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
9,878,565.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
9,878,565.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
9,878,565.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.3 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: Represented by 3,292,855 ADSs (as defined in Item 2(a)) (includes 1,500,000 Shares (as defined in Item 2(a)) (underlying 500,000 ADSs) issuable upon exercise of call options).
SCHEDULE 13G
CUSIP Number(s):
G8128Y157
1
Names of Reporting Persons
Tetragon Financial Management LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
9,878,565.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
9,878,565.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
9,878,565.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.3 %
12
Type of Reporting Person (See Instructions)
IA, PN
Comment for Type of Reporting Person: Represented by 3,292,855 ADSs (includes 1,500,000 Shares (underlying 500,000 ADSs) issuable upon exercise of call options).
SCHEDULE 13G
CUSIP Number(s):
G8128Y157
1
Names of Reporting Persons
Patrick G. G. Dear
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED KINGDOM
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
9,878,565.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
9,878,565.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
9,878,565.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.3 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: Represented by 3,292,855 ADSs (includes 1,500,000 Shares (underlying 500,000 ADSs) issuable upon exercise of call options).
SCHEDULE 13G
CUSIP Number(s):
G8128Y157
1
Names of Reporting Persons
Reade E. Griffith
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED KINGDOM
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
9,878,565.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
9,878,565.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
9,878,565.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.3 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: Represented by 3,292,855 ADSs (includes 1,500,000 Shares (underlying 500,000 ADSs) issuable upon exercise of call options).
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Silence Therapeutics plc
(b)
Address of issuer's principal executive offices:
12 Hammersmith Grove, London W6 7AP, United Kingdom
Item 2.
(a)
Name of person filing:
This statement is filed by:
i. Tetragon Financial Group Limited ("Tetragon"), a Guernsey company, with respect to the Ordinary Shares, nominal value 0.05 GBP per share (the "Shares") held in the form of American Depositary Shares ("ADSs") and the Shares underlying ADSs issuable upon exercise of call options directly held by it;
ii. Tetragon Financial Management L.P. ("Tetragon Manager"), a Delaware limited partnership, as the investment manager of Tetragon, with respect to the Shares held in the form of ADSs and the Shares underlying ADSs issuable upon exercise of call options directly held by Tetragon;
iii. Patrick G. G. Dear ("Mr. Dear"), as principal to Tetragon Manager, with respect to the Shares held in the form of ADSs and the Shares underlying ADSs issuable upon exercise of call options directly held by Tetragon; and
iv. Reade E. Griffith ("Mr. Griffith"), as principal to Tetragon Manager, with respect to the Shares held in the form of ADSs and the Shares underlying ADSs issuable upon exercise of call options directly held by Tetragon.
Each ADS represents three Shares.
This Amendment No. 1 amends and restates the original statement on Schedule 13G filed by the Reporting Persons on October 13, 2026.
(b)
Address or principal business office or, if none, residence:
The address of the principal office of each of Tetragon and Messrs. Dear and Griffith is c/o Tetragon Partners UK LLP, 4 Sloane Terrace, London SW1X 9DQ, United Kingdom. The address of the principal office of Tetragon Manager is 399 Park Avenue, 22nd Floor, New York, New York 10022.
(c)
Citizenship:
Tetragon is a Guernsey company. Tetragon Manager is a Delaware limited partnership. Messrs. Dear and Griffith are citizens of the United Kingdom.
(d)
Title of class of securities:
Ordinary Shares, nominal value 0.05 GBP per share
(e)
CUSIP No.:
G8128Y157
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 186,461,401 Shares outstanding, as reported in the Company's, Prospectus filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission on August 12, 2026 and in the Company's press release dated as of August 14, 2026, after giving effect to the completion of the offering and the full exercise of the underwriters' over-allotment option, all as described therein.
(b)
Percent of class:
5.3%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(ii) Shared power to vote or to direct the vote:
The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(iii) Sole power to dispose or to direct the disposition of:
The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(iv) Shared power to dispose or to direct the disposition of:
The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
See Item 2(a).
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
See Item 2(a).
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
